Anybody listen to the presentation today (Piper Jaffray)? All the questions related to Epidolex for epilepsy in kids. The company skillfully avoided answering the big question - does it work? What it points out to me is the flawed drug approval program in the USA. If it works, you have to keep it quiet while you navigate the various demands of the Federal government. Otherwise, parents will demand access (they already are) and a media firestorm will erupt focusing on the cold hearted FDA, DEA, etc. Of course it works (at least 50%). But the kids will just have to wait until all forms are filled out and approved by people who don't really like this whole cannabis thing.
Dec. 5th there will be 1.3 Million new ordinary shares (London) as part of the employee stock incentive programs. Less than 1 percent dilution, but still seems to have spooked investors. Look at the chart for GWPH.L - this was announced Nov. 29 and the stock immediately headed lower. Probably a good opportunity.
This being a public forum, I probably shouldn't bring attention to certain strategies and tactics. Yeah - it's Yahoo. But you never know. I just want to make some money on something (high CBD cannabis) that was revealed to me during a personal tragedy. Keep posting.
Sentiment: Strong Buy
We are in a quiet period with no news. The volume is very low, so it can drift up or down for no particular reason. I think there is a little accumulation coming from somewhere. Yesterday, half the volume came is one trade of 12,351 shares. That looks like accumulation to me.
Thanks for the info. I knew most of what was in the presentation, but the numbers relating to epilepsy in kids was new to me. A very small sample, but more that 50% had seizure reduction of greater than 80%. That's a big number in the drug business. Looks like more info will be coming soon. BTW, the FDA and DEA are just roadblocks to progress. CBD should already be available and legal - it's harmless.
All the small companies with an FDA SPA agreement are taking a hit today after the FDA reneged on it's SPA with AMRN. It's the end of AMRN and puts a cloud over all small biopharma companies. But GWPH is different than AMRN in many ways. Cannabinoids and fish oil are worlds apart. This is probably a good buying opportunity.
GWPH is so far ahead of GWP (London). GWPH would be $30.50 if it was tracking GWP. London is going to need to catch up or GWPH needs to come down. This has been going on ever since GWPH started moving up from $10.
Here we go. FDA is allowing even more epilepsy patients to use GW's Epidiolex (98% CBD) for what is rapidly becoming a Phase III "field trial". Apparently, the drug is working very well in the severe cases of pediatric epilepsy already on the FDA's program that provides Epidolex to these kids. Well, that was fast.
Appetite suppression is a tricky area. Inhibiting a normal body function could result in unintended consequences. Obesity is almost always a lifestyle issue. Besides, there are more inflammatory diseases than you can count and cannabidiol reduces inflammation.
London trades much differently. Smoother. I wonder about the integrity of Nasdaq markets. All of Wall Street for that matter. The cowboy at Lazard comes out with this crazy price target ($65), and Canaccord comes out with a one year target of $26 the same day. Guess which was reported? Listen to the last conference call. Canaccord asks the tough questions - real pros. I'll wait.
It looks to me like London is leading now. London was trading GWP at 129 (equals $24.67 per GWPH) and GWPH was in lock step. As soon as London closed, they started running up GWPH. GWP looks like it wants to go lower to me, so GWPH is probably going to sell off tomorrow. This is a complicated and fluid situation. We did close the gap at $24, but I'm thinking we can see the teens again. Briefly.
I'd like to own GW long term. If we can get rid of the fickle fast money guys, I'll buy it back. This volatility makes me anxious (and suspicious).